Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047088 | 1.00 | NQO2 (0.40) | NQO2NAMPTDRD2ACETDP1 | |
| SCHEMBL14092157 | 0.91 | NQO2 (0.42) | NQO2NAMPTDRD2TDP1MTNR1A | |
| SCHEMBL14092255 | 0.82 | CYP3A4 (0.39) | TDP1MIFCYP3A4 | |
| SCHEMBL14092135 | 0.82 | HTT (0.46) | ACEMTNR1AMTNR1B | |
| SCHEMBL14047099 | 0.82 | ACE (0.38) | NQO2NAMPTDRD2ACEMTNR1A | |
| SCHEMBL14047098 | 0.81 | EPHX1 (0.35) | NQO2NAMPTDRD2ACETDP1 | |
| SCHEMBL4445600 | 0.80 | MTNR1B (0.40) | NAMPTMTNR1AMTNR1B | |
| SCHEMBL13272194 | 0.77 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL12377772 | 0.77 | L3MBTL1 (0.39) | TDP1 | |
| SCHEMBL18505012 | 0.77 | L3MBTL1 (0.39) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | NQO2 4220/4885NAMPT 4088/4885DRD2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.